Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262041 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 524
- Enrollment target
NCT00262041 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 524 participants.
The verdict
NCT00262041, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 524 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to 17 years.
Interventions
- BIOLOGICAL MenACWY-CRM conjugate vaccine, adjuvanted
- BIOLOGICAL MenACWY-CRM conjugate vaccine, unadjuvanted
- BIOLOGICAL MenACWY polysaccharide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262041
The ClinicalTrials.gov registry entry for NCT00262041 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 524 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MenACWY-CRM conjugate vaccine, adjuvanted is the first listed.
NCT00262041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262041 about?
NCT00262041 is a clinical study titled "Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents". The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to 17 years.
What is the current status of trial NCT00262041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 524 participants. The study started on 2004-10. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00262041?
The interventions under investigation include: MenACWY-CRM conjugate vaccine, adjuvanted (BIOLOGICAL), MenACWY-CRM conjugate vaccine, unadjuvanted (BIOLOGICAL), MenACWY polysaccharide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00262041?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.